Podocyte Talk - Dr. Anass Qasem
@podocytetalk.bsky.social
Podocyte Talk is your go-to channel for in-depth discussions on cutting-edge kidney disease research and clinical innovations. Join us weekly as we explore groundbreaking studies, novel therapies, and practical insights into nephrology. #Nephsky
🔹 Calcitriol in IgA Nephropathy. 🔹 Finerenone Pooled Outcomes (FINE-HEART analysis). 🔹 Real-World Risk of Kidney Failure vs. Death in Diabetes. #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/EPO_Wf_nz2w
Episode 32 - Vitamin D, Finerenone & Kidney Failure Risk in Diabetes: New Evidence in CKD Care
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
In this episode of Podocyte Talk, we delve into three important studies shaping the management of advanced chronic kidney disease (CKD): 🔹 Exercise Before Dialysis 🔹 Cost-Effectiveness of Low-Protein Diets 🔹 Spironolactone in CKD #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/NFMi6Ysez5w
Episode 30 - Exercise, Diet, and Spironolactone in CKD: What's the Latest?
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
In Episode 29 of Podocyte Talk, we cover three high-impact studies: Measured GFR After Bariatric Surgery Pregnancy and Long-Term Kidney Function in Chronic Kidney Disease Dapagliflozin and Health-Related Quality of Life #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/yUfhuKXL_-s
Episode 29 - GFR After Bariatric Surgery, Pregnancy in CKD, and DAPA Quality of Life Benefits
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
In Episode 28 of Podocyte Talk, we discuss three clinically relevant studies advancing care in nephrology and transplant medicine: Intradialytic Exercise Trial . EVEREST Post-Hoc Analysis. Transplant Infection Study (India). #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/LEh0boi4Ovc
Episode 28 - Exercise During Dialysis, Kidney Function in Heart Failure, and Transplant Infections
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
🎙️New #PodocyteTalk! GLP-1 RAs reduce death & boost transplant listing in dialysis. Biomarkers predict CKD outcomes. Sotradecol foam shrinks cysts in ADPKD/ADPLD. 📺 Watch & subscribe—85% of viewers still haven’t! 🔗 youtu.be/GKCeZsl1s2M #nephrology #CKD
Episode 27 - GLP-1 RAs in Dialysis, Biomarkers in CKD, and Foam Sclerotherapy in Polycystic Disease
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
🎙️ In Ep. 26 of Podocyte Talk: – Finerenone + empagliflozin: better together in DKD – Hypoglycaemia common post-dialysis in older adults – Tirzepatide lowers albuminuria in obesity, with/without diabetes Listen now! #CKD #Nephrology #Diabetes #GLP1 youtu.be/NiNvQYVdhIw
Episode 26 - Can We Do More for Diabetic Kidneys?
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
Dual therapy with finerenone + empagliflozin cut albuminuria by ~30% more than either drug alone in CKD + T2D—with no added safety concerns. A promising step for combo treatment in DKD. #CKD #T2D #SGLT2i #Finerenone #CONFIDENCE #Nephrology #BlueskyMD
Episode 25 of Podocyte Talk is out! 🎧 Albuminuria predicts AF in the elderly 💉 Rituximab shows >95% 10-yr renal survival in MN 🫁 Pre-KTx pulmonary HTN = higher graft loss Smart nephrology insights you can use. #CKD #Nephrology #Podcasts youtu.be/EO0eLgu6uuw
Episode 25 - Early Albuminuria and AF | Long-Term Rituximab in MN | Pulmonary HTN & Transplant Risk
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
Podocyte Talk Episode 24: – SGLT2i vs GLP-1RA in real-world CKD care – Finerenone works regardless of early eGFR drop – High-carb diets raise mortality in dialysis patients #Nephrology #KidneyCare #Finerenone #SGLT2i #GLP1RA #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/uMbtbhPYBPc
Episode 24 - SGLT2i vs GLP-1RA, Finerenone & eGFR Drop, and Carbs in Dialysis
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
Simultaneous initiation of SGLT2i, RASi, ns-MRA, and GLP1-RAs presents a promising approach to mitigate the risk of CV events and the progression of kidney disease in patients with CKD. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/jasn/abstrac...
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/cjasn/abstra...
Patients receiving SGLT2i demonstrated lower rates of progression to KRT compared to those receiving GLP1RA. These findings may inform the choice of these therapies in the setting of CKD and T2DM. #podocytetalk #Nephpearls #Nephrology #CKD #nephsky www.ajkd.org/article/S027...
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes...
Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular, kidney, and survival outcomes in patients with type 2 diabetes; ...
ajkd.org
In patients with CKD and T2DM, finerenone reduced cardiovascular and kidney events regardless of whether eGFR rose or declined in the first month. Even with >10% acute eGFR drop, benefits were preserved. #podocytetalk #CKD #Nephsky www.kidney-international.org/article/S008...
Analysis of the prespecified FIDELITY pooled patient dataset examined the efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate.
The efficacy and safety of finerenone (a non-steroidal mineralocorticoid receptor antagonist) versus placebo were assessed according to different changes in estimated glomerular filtration rate (eGFR)...
kidney-international.org
In a diverse IgAN cohort, 36% reached kidney failure, major eGFR decline, or died within 2.7 years. Proteinuria ≥0.5 g/g strongly predicted poor outcomes, challenging past beliefs that <1 g/g is low risk. #podocytetalk #Nephpearls #Nephrology #CKD #nephsky academic.oup.com/ndt/advance-...
Kidney outcomes were poor in genetic nephrotic syndrome; in FSGS outcomes were strongly associated with proteinuria level. MCD patients had better proteinuria control than FSGS and had better outcomes at each proteinuria level. #podocytetalk #Nephpearls #nephsky journals.lww.com/jasn/abstrac...
In IgA nephropathy, dapagliflozin slowed eGFR decline, especially in patients with faster pre-treatment loss. The pre-treatment eGFR slope predicted post-treatment benefit, suggesting value in guiding therapy. #podocytetalk #CKD #GN #Nephsky www.kireports.org/article/S246...
Pre-treatment GFR slopes predict dapagliflozin response in IgA nephropathy
Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pre-treatment estimated glomerular filtration rate (eGFR) slope and post-treat...
kireports.org
In CKD, furosemide use—especially >100 mg/day—is linked to higher serum levels of protein-bound uraemic toxins like IS, PCS, Kyn, and IAA. Furosemide may impair toxin clearance via OAT1/3 transporters, contributing to toxin accumulation. #podoctyetalk #CKD #Nephsky www.kireports.org/article/S246...
Furosemide and Serum Protein-Bound Uraemic Toxin Concentrations in Patients with Chronic Kidney Disease
Furosemide is commonly prescribed to patients with CKD but may impair the kidney’s excretion of protein-bound uraemic toxins (PBUTs) via the organic anion transporters 1 and 3 (OAT1/OAT3). We evaluate...
kireports.org
In Episode 23 of Podocyte Talk, we dive into three important new studies: use of finerenone in IgA nephropathy, incidence and outcomes of acute kidney injury in very old patients, and risk of UTIs with SGLT2 inhibitors #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/X5dh2G-FAuI
Episode 23 - Finerenone in IgA Nephropathy, AKI in the Very Old, and SGLT2i UTI Risks
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
Podocyte Talk is now twice monthly! Each episode includes 2 multiple-choice questions—answer in the comments and test your nephrology knowledge! In this episode, we explore three impactful studies in nephrology #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/C1MQgOdVdv4
Episode 22 - Phosphate Binders, Cancer Risk & Early Treatment in CKD – Test Yourself with 2 MCQs
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
✅ SGLT2 inhibitors in patients with advanced CKD ✅ Anti-nephrin antibodies as relapse predictors in MCD & FSGS ✅ Sacubitril/valsartan improves dialysis access flow in heart failure #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/YkNoV6CDmxU
Episode 21 - Breakthroughs in Kidney Care: SGLT2i in CKD, New Biomarkers, and Better Dialysis Flow
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
Among low-risk patients undergoing PCI, contrast-associated AKI was rare, and withholding or continuing SGLT2 inhibitors had no impact on AKI risk or renal function. discontinuation in this setting may not be necessary. journals.lww.com/kidney360/pa... #Podocytetalk @asnpublications.bsky.social
This study highlights the negative impact of hypertension early after kidney transplantation and emphasizes the importance of effective treatment to improve long-term graft and patient survival. www.kireports.org/article/S246... #Podocytetalk #nephrology #CKD #Nephsky
BP targets post kidney transplant, SGLT2i use in angiography, and CGM insights in dialysis—all in Ep. 20 of Podocyte Talk. Tune in for key updates in nephrology! 🎧 #Nephrology #KidneyCare #podocytetalk #Nephpearls #nephsky youtu.be/fW2Ug1Sk9Rk
Episode 20 - BP Target in renal transplant, SGLT2i with contrast, and Glucose Monitoring in Dialysis
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
This week, we break down three major nephrology studies: ✅ Obinutuzumab’s role in lupus nephritis ✅ Best phosphate binders for dialysis patients ✅ Long-term effects of tolvaptan in ADPKD #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/86pdnfUKlsA
Episode 19 - Lupus nephritis, Phosphate Binders & Tolvaptan: Key Updates in Nephrology!
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
A JASN study links higher CKM stages to increased 15-year CV mortality (Stage 0: 5.5%, Stage 4: 15.2%). Stage 4 had a 9.6% higher risk. Early intervention is crucial. journals.lww.com/jasn/pages/a... #Podocytetalk #Nephrology #CKM
Tolvaptan slowed kidney function decline by 14%, reducing eGFR loss over time. However, it did not significantly impact total kidney volume (TKV) growth. Patients with higher osmolar intake showed a greater treatment response #Podocytetalk #nephsky #nephrology academic.oup.com/ndt/advance-...
The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD
AbstractBackground and hypothesis. The only therapy to ameliorate disease progression in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
academic.oup.com
In this episode of Podocyte Talk, we explore the impact of obesity on polycystic kidney disease progression, the predictive power of albuminuria in IgA nephropathy, and how tacrolimus metabolism affects kidney transplant outcomes #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/cFq0B8kr_ZU
Episode 18 - Overweight, Albuminuria, and immunosuppression Metabolism in Kidney Disease
YouTube video by Podocyte Talk - Dr. Anass Qasem
youtu.be
In patients with HRS-1 who are adequately treated with norepinephrine and achieved an optimal MAP increment, addition of i.v. furosemide enhances diuresis without negatively affecting renal recovery. www.kireports.org/article/S246... #podocytetalk #Nephpearls #Nephrology #CKD #nephsky
Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1
Diuretics are commonly discontinued in patients with cirrhosis with acute kidney injury (AKI) because they are presumed to trigger hepatorenal syndrome type 1 (HRS-1). We hypothesized that if HRS-1 is...
kireports.org